Thirty, out of the 34 papers classified as product technologies addressedtechnologies directed to the prevention of PPH, including eight papers that accessedthe isolated use of misoprostol; four addressed the use of oxytocin throughdifferent routes and dosages; 12 studies compared misoprostol to oxytocin; twostudies compared carbetocin to syntometrine; one analyzed ergometrineversus oxytocin; one ergometrine versusoxytocin versus misoprostol; one addressed PGF2α (ProstaglandinF2α) versus misoprostol; and one compared ZB11 (ZhiByed 11– Tibetan traditional medicine) to misoprostol. The gene discussed is OXT; the disease is pulmonary arterial hypertension.